Treatment of clinically isolated syndrome: to be PreCISe.
Miller
David H
DH
Department of Neuroinflammation, UCL Institute of Neurology, London WC1N 3BG, UK. d.miller@ion.ucl.ac.uk
Leary
Siobhan M
SM
D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome
D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta